| Similar Articles |
|---|
 |
The Motley Fool
June 16, 2005
Karl Thiel |
BiDil's Bid for a Narrow Label Although things appear to be going NitroMed's way, there is a dark horse spoiler looming in the shadows that should keep investors on their toes today. The company is seeking FDA approval for African-Americans only, but what if BiDil is given a broader label acceptance?   |
The Motley Fool
August 2, 2004
W.D. Crotty |
NitroMed: The New Taser? A new cardiac drug springs this stock into an eye-opening run. |
Bio-IT World
January 21, 2005 |
The Race Prescription Card The FDA is on the verge of approving a heart disease drug called BiDil that is particularly effective in African-Americans. Some see this as a an effort to address health inequalities while others view it as a first step en route to racial discrimination. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency. |
Managed Care
February 2008
Martin Sipkoff |
FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process? |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Bio-IT World
April 2006
Kevin Davies |
NitroMed Ties Gene Biomarkers to BiDil Benefit The FDA approval of BiDil, NitroMed's heart failure drug for blacks, raised howls of controversy. Now at a meeting of the American College of Cardiology, researchers presented two papers that offer the first preliminary hints of genetic factors that affect BiDil response. |
BusinessWeek
June 27, 2005
Amy Barrett |
Color-Blind Drug Research Is Myopic Researchers will sometimes have to use the blunt instrument of race to help match patients with the right drugs. |
